How does it work?

1. The tissue from your most recent biopsy or lumpectomy is sent to our lab for analysis. No additional procedures are required.

2. Test results are sent to your doctor.

3. You and your doctor review the results together.

Learn More About Your Insurance Options

To learn about Medicare coverage, private insurance coverage, and financial assistance, contact our Customer Service group by phone at:
888-ONCOTYPE (888-662-6897)
– select option 2
or by email at:
oncotype@exactsciences.com

Exact Sciences offers financial assistance for eligible patients. If eligible, both insured and uninsured patients will have no out-of-pocket costs.

Scan here to see if you’re eligible for testing at no cost, or visit:
ExactSciencesPO.com/assistance
for more information.

If you would like to share your story with other patients about your experience with the Oncotype DX DCIS Score® test, please contact us at:
patientstories@exactsciences.com

Stage zero ductal carcinoma in situ

Do you really need radiation for your DCIS?

Exact Sciences

Oncotype DX, Oncotype DX Breast DCIS Score, and DCIS Score are registered trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences is a registered trademark of Exact Sciences Corporation. © 2022 Genomic Health, Inc. All rights reserved.


This educational piece is not designed to provide individual advice in connection with your diagnosis or treatment plan. Talk to your health care provider about such matters and whether the Oncotype DX DCIS Score test may be right for you. Individual results may vary.
**Why Did My Doctor Order This Test?**

When it comes to treatment decisions for your stage zero ductal carcinoma in situ breast cancer (DCIS), you have a few treatment options. Many patients choose to have a lumpectomy. Doctors frequently recommend radiation therapy after this surgery to reduce the chance of your DCIS coming back. But radiation can have side effects and life-changing complications. The Oncotype DX Breast DCIS Score® test can help you and your doctor identify the risk of your cancer coming back and design a personalized treatment plan based on the biology of your tumor.

**Genomic Testing – The Key to Knowing Your Cancer**

Unlike a genetic test which assesses your hereditary risk for cancer, a genomic test analyzes cancer tissue to provide information on how a tumor might behave. It identifies changes in DNA that may be driving the growth of your tumor. The DCIS Score® test examines specific genes found inside your DCIS to determine the aggressiveness of the individual tumor and can predict the risk of a recurrence of either DCIS or invasive breast cancer.

**Pioneering Research**

In a large study, the Oncotype DX Breast DCIS Score test showed that 70% of women are at low risk for recurrence and may be able to forego radiation therapy. The Oncotype DX Breast DCIS Score test can help women and their doctors confidently choose the most appropriate treatment, helping many patients avoid the consequences and cost of unneeded radiation therapy, while identifying those who need more aggressive treatment.

**What Can I Expect from My Test Results?**

Your results are reported as a Breast DCIS Score result based on a scale of 0-100. This unique score, refined by your age and your tumor size, indicates how likely your DCIS is to return in the same breast during the next 10 years as either DCIS or invasive breast cancer following your lumpectomy. The lower your score, the lower the likelihood your cancer will come back in that breast. Your DCIS Score report also includes the expression of the estrogen and progesterone receptors in your DCIS so you can make informed hormone therapy decisions. Make sure to review your test results with your doctor.

Over 1 million breast cancer patients have used an Oncotype DX® test to help guide their treatment decisions.  

---

1- Solin, JNCI, 2013  
2- Data on file.
Why Did My Doctor Order This Test?

When it comes to treatment decisions for your stage zero ductal carcinoma in situ breast cancer (DCIS), you have a few treatment options. Many patients choose to have a lumpectomy. Doctors frequently recommend radiation therapy after this surgery to reduce the chance of your DCIS coming back. But radiation can have side effects and life-changing complications. The Oncotype DX Breast DCIS Score® test can help you and your doctor identify the risk of your cancer coming back and design a personalized treatment plan based on the biology of your tumor.

Genomic Testing – The Key to Knowing Your Cancer

Unlike a genetic test which assesses your hereditary risk for cancer, a genomic test analyzes cancer tissue to provide information on how a tumor might behave. It identifies changes in DNA that may be driving the growth of your tumor. The DCIS Score® test examines specific genes found inside your DCIS to determine the aggressiveness of the individual tumor and can predict the risk of a recurrence of either DCIS or invasive breast cancer.

Pioneering Research

In a large study,1 the Oncotype DX Breast DCIS Score test showed that 70% of women are at low risk for recurrence and may be able to forego radiation therapy. The Oncotype DX Breast DCIS Score test can help women and their doctors confidently choose the most appropriate treatment, helping many patients avoid the consequences and cost of unneeded radiation therapy, while identifying those who need more aggressive treatment.

What Can I Expect from My Test Results?

Your results are reported as a Breast DCIS Score result based on a scale of 0-100. This unique score, refined by your age and your tumor size, indicates how likely your DCIS is to return in the same breast during the next 10 years as either DCIS or invasive breast cancer following your lumpectomy. The lower your score, the lower the likelihood your cancer will come back in that breast. Your DCIS Score report also includes the expression of the estrogen and progesterone receptors in your DCIS so you can make informed hormone therapy decisions. Make sure to review your test results with your doctor.

Over 1 million breast cancer patients have used an Oncotype DX® test to help guide their treatment decisions.2

1 - Solin, JNCI, 2013
2 - Data on file.
How does it work?

1. The tissue from your most recent biopsy or lumpectomy is sent to our lab for analysis. No additional procedures are required.
2. Test results are sent to your doctor.
3. You and your doctor review the results together.

Learn More About Your Insurance Options

To learn about Medicare coverage, private insurance coverage, and financial assistance, contact our Customer Service group by phone at: 888-ONCOTYPE (888-662-6897) – select option 2 or by email at: oncotype@exactsciences.com

Exact Sciences offers financial assistance for eligible patients. If eligible, both insured and uninsured patients will have no out-of-pocket costs.

Scan here to see if you're eligible for testing at no cost, or visit ExactSciencesPO.com/assistance for more information.

If you would like to share your story with other patients about your experience with the Oncotype DX DCIS Score® test, please contact us at: patientstories@exactsciences.com

Do you really need radiation for your DCIS?

Stage zero ductal carcinoma in situ

Breast Cancer

Breast DCIS Score

by EXACT SCIENCES

Oncotype DX, Oncotype DX Breast DCIS Score, and DCIS Score are registered trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences is a registered trademark of Exact Sciences Corporation. © 2022 Genomic Health, Inc. All rights reserved.


This educational piece is not designed to provide individual advice in connection with your diagnosis or treatment plan. Talk to your health care provider about such matters and whether the Oncotype DX DCIS Score test may be right for you. Individual results may vary.
Do you really need radiation for your DCIS?

1. The tissue from your most recent biopsy or lumpectomy is sent to our lab for analysis. No additional procedures are required.
2. Test results are sent to your doctor.
3. You and your doctor review the results together.

Learn More About Your Insurance Options

Patients have **$0 financial responsibility** for DCIS Score test when Medicare fee-for-service (FFS) coverage criteria are met.

Medicare Advantage, which is provided by commercial insurance companies, may have different financial responsibility compared to Medicare FFS.

To learn about Medicare coverage, private insurance coverage, and other financial options, contact our Customer Service group by phone at:

**888-ONCOTYPE (888-662-6897)**

– select option 2

or by email at:

**oncotype@exactsciences.com**

If you would like to share your story with other patients about your experience with the Oncotype DX DCIS Score test, please contact us at:

**patientstories@exactsciences.com**